Lv41
404 积分 2022-11-14 加入
Dose-dense temozolomide for newly diagnosed glioblastoma: a randomized phase III clinical trial
2天前
已完结
Tumor treating fields plus temozolomide for newly diagnosed glioblastoma: a sub-group analysis of Korean patients in the EF-14 phase 3 trial
1个月前
已完结
Four-Year Outcomes of First-Line Nivolumab Plus Ipilimumab for 6 Months Versus Continuation in Patients With Advanced NSCLC: Results of the Randomized IFCT-1701 “DICIPLE” Phase III Trial
1个月前
已完结
PET-based response assessment criteria for diffuse gliomas (PET RANO 1.0): a report of the RANO group
2个月前
已完结
Real-world outcomes of immunotherapy discontinuation at two years in advanced non-small cell lung cancer: Final results of the I-STOP study
2个月前
已完结
First-Line Tislelizumab Plus Chemotherapy Versus Placebo Plus Chemotherapy in Extensive-Stage SCLC: A Long-Term Survival and Programmed Death-Ligand 1 Subgroup Analysis From the Randomized, Phase 3 RATIONALE-312 Trial
2个月前
已完结
Management guideline for the off-label use of medicine in China (2021)
2个月前
已完结
Comparison of patient data in parallel records: The sign-out sheet and the electronic medical record
3个月前
已完结
Camrelizumab plus rivoceranib versus sorafenib as first-line therapy for unresectable hepatocellular carcinoma (CARES-310): a randomised, open-label, international phase 3 study
3个月前
已完结
Modification and validation of the Birmingham Vasculitis Activity Score (version 3)
3个月前
已完结
皖公网安备34019202002308
